In 1998, George Vande Woude's lab discovered that anthrax lethal factor (LF), the principal virulence component of anthrax toxin, was a zinc-metalloprotease that cleaved and inactivated mitogen-activated protein kinase kinases (MKK). It was perhaps not surprising, given the known roles of MKK1 and 2 in cell proliferation, that LF was subsequently found to dramatically inhibit tumor growth in vivo. What was not anticipated, however, was that the tumors treated with LF would have a substantially reduced vascular content. This intriguing result was one of the first indications that MKK signaling plays an important role in promoting tumor vascularization in vivo. In the following short review, we will compare in vitro and in vivo evidence that supports the hypothesis that MKK signaling pathways are essential for vascularization.
Introduction
The mitogen-activated protein kinase kinase (MKK) signaling pathways are a group of related protein kinase signaling cascades that are widely expressed in eukaryotes including fungi, plants and animals (Davis, 2000; Chang and Karin, 2001; Chen et al., 2001; Johnson and Lapadat, 2002; Roux and Blenis, 2004) . For epistemological reasons, MKK signaling pathways have been organized into modules, each of which contains a threetiered kinase cascade comprising a mitogen-activated protein kinase kinase kinase (MAPKKK, MEKK or MKKK), a mitogen-activated protein kinase kinase (MAPKK, MEK or MKK) and a mitogen-activated protein kinase (MAPK) . In response to extracellular stimuli such as growth factors or cytokines, ligand: receptor-binding initiates activation of MKKK that phosphorylate MKK, that in turn phosphorylate MAPK. Phosphorylated/activated MAPK then phosphorylate effector molecules that may act at the transcriptional, post-transcriptional or post-translational levels. The most extensively studied vertebrate MAPK to date are the extracellular signal-regulated kinases (ERK 1 and 2) that are activated by MEK1 and 2, the p38 MAPK that are activated by MKK 3 and 6, and the jun kinases (JNK) that are activated by MKK4 and 7. More recently, ERK5, a target of MEK5, has emerged as a focus of interest.
Numerous in vitro studies have linked MKK signaling to both the transcriptional and the post-translational regulation of vital cellular processes including cell differentiation, proliferation, motility and survival. By contrast, only a handful of studies have attempted to address the functions of these signaling pathways in vivo and fewer yet have considered the complex biology that may arise as a consequence of crosstalk between these pathways within a cell, tissue, organ or whole organism. In the following discussion, we will review and compare in vitro and in vivo evidence that supports the hypothesis that MKK signaling pathways are essential for vascularization.
MKK signaling and tumor vascularization
Tumor vasculature arises through a process known as angiogenesis in which existing blood vessels are recruited (Lyden et al., 2001) , remodelled (Ergun et al., 2001) or co-opted (Holash et al., 1999) to provide a blood supply to avascular tumor tissues. During angiogenesis endothelial cells proliferate, produce proteolytic enzymes that degrade the extracellular matrix, change their adhesive properties, migrate and differentiate into new blood vessels. This process of tumor vascularization is directed mainly by paracrine angioproliferative tumor factors and extracellular matrix components that bind to specialized receptors such as G-protein-coupled receptors or receptor tyrosine kinases and integrins on endothelial cells (Eliceiri et al., 1998; Ruegg and Mariotti, 2003; Kowanetz and Ferrara, 2006) . Ligand activation of these receptors triggers signaling pathways leading to altered protein activity and gene transcription that modulate the cellular behavior.
One such angio-proliferative factor, vascular endothelial growth factor A (VEGF), plays a crucial role in regulating tumor angiogenesis. In vitro, VEGF is a potent mitogen of endothelial cells (Connolly et al., 1989; Ferrara and Henzel, 1989) . In vivo, intradermal injection of VEGF causes increased vascular permeability (Senger et al., 1983) . Inhibition of VEGF release from tumors leads to decreased tumor vasculariztion and growth (Kim et al., 1993) and embryonic stem cells that are homozygous null for VEGF are unable to form tumors in nude mice (Ferrara et al., 1996) . VEGF also plays an important role in embryonic development. Mice lacking only a single copy of VEGF die between E11 and E12 as a result of extensive vascular defects in both the embryo and placenta (Carmeliet et al., 1996; Ferrara et al., 1996) . Moreover, whereas homozygous gene targeting of the VEGF receptor VEGFR2 (Flk-1) causes embryonic lethality at E8.5-9.5 that is characterized by the absence of organized blood vessels in the embryo and yolk sac (Shalaby et al., 1995) , embryos that are homozygous null for the alternate VEGF receptor VEGFR1 (Flt-1) die at E8.5 with abnormally large blood vessels (Fong et al., 1995 (Fong et al., , 1999 .
A substantial body of evidence indicates that MKK signaling pathways play essential roles in modulating the release of, and the response to VEGF. MKK activity regulates VEGF expression at the transcriptional and post-transcriptional levels (Pages et al., 2000) . Expression of constitutively active MEK1 in fibroblasts elevates expression of VEGF mRNA through binding of the transcription factors Sp1 and AP-2 to its promoter region (Milanini et al., 1998) . Also, VEGF mRNA half-life is increased in cells that overexpress p38 MAPK and JNK (Pages et al., 2000) . MKK signaling pathways are also activated in response to VEGF; treatment of endothelial cells with VEGF has been observed to cause activation of both ERK 1 and 2 (D'Angelo et al., 1995) as well as p38 MAPK (Rousseau et al., 1997) . Moreover, this increase in MKK activity is required for endothelial response to VEGF. Whereas MEK1/2 inhibitors prevent VEGF-induced cell proliferation (Rousseau et al., 1997; Pedram et al., 1998) , p38 MAPK inhibitors reportedly prevent VEGF-induced cytoskeletal re-organization and cell migration (Rousseau et al., 1997) . The JNK pathway has also been linked to in vitro endothelial cell motility (Shin et al., 2001; Ennis et al., 2005) and proliferation (Ennis et al., 2005) .
Despite evidence of a strong link between MKK signaling, endothelial cell function, and the release of angio-proliferative factors in vitro, the role MKK play in promoting tumor vascularization in vivo is less clear. Insight into their in vivo functions may be inferred from the effects of MKK inhibitors upon tumor vascularization. For example, anthrax lethal factor, a protease that inactivates MEK1 and 2 (Duesbery et al., 1998) as well as MKK 3, 4, 6, and 7 (Vitale et al., 2000) , substantially inhibits vascularization in mouse xenograft studies (Duesbery et al., 2001) . Its antiendothelial effects result not only from its ability to inhibit MKK signaling but also from the upregulation of anthrax toxin receptors in tumor-associated endothelium (St Croix et al., 2000; Bradley et al., 2001) . Also, expression of an inactive Raf-1 mutant in endothelial cells blocks growth and vascularization of melanomas in mice (Hood et al., 2002) . BAY 43-9006 (Sorafenib), a compound that inhibits B-Raf and c-Raf, MKKK that activate MEK 1 and 2, also reduces tumor vascularization in vivo (Wilhelm et al., 2004) . However, whether this is owing directly to inhibition of MKK signaling is unclear as (1) an antiangiogenic effect has not been reported for other MEK 1 and 2 inhibitors such as CI1040 (PD184352) and (2) BAY 43-9006 can also inhibit the activity of the VEGF receptor, VEGFR2 (Wilhelm et al., 2004) . Additional clues come from knockout studies with mice. Tumors growing in host mice that are deficient in ERK5 expression are not only reduced in size but also have a reduced vasculature (Hayashi et al., 2005) . Although these limited studies indicate that MKK signaling likely plays a role in tumor vascularization, they do not discriminate whether all pathways are indispensable or whether particular pathways are more important than others. Further insight into the in vivo roles of MKK signaling in vascularization can be gleaned from studies that have examined their participation in normal developmental processes.
MKK signaling and blood vessel development during early embryogenesis
Initially it had been expected that picking out direct relationships between MAPK function and development would be complicated by extensive crosstalk between the different MKK pathways as well as overlapping and redundant functions of MAPK isoforms. However, studies of MKK pathway knockout mice, although pointing to a common role in regulating vascularization and blood vessel development during early embryogenesis, have revealed a surprising level of independence between these pathways (Table 1) .
Gene targetting of BRAF causes embryonic death between E10.5 and 12.5 (Wojnowski et al., 1997) . These embryos displayed extensive vascular defects including irregularly shaped large blood vessels that were incompletely lined with endothelial cells. Raf-1 knockout mice die in utero at E10 with diminished vascularization of the embryo and placenta (Huser et al., 2001; Mikula et al., 2001) . Targeted deletion of Mekk3, a MKKK that can activate MEK5 and ERK5 as well as MKK3 and p38MAPK, causes embryonic death at E11 that is characterized by extensive defects in blood vessel formation in the embryo, placenta and yolk sac, while not affecting VEGF expression .
MEK1 knockout mice die in utero at E10.5 owing to defects in placental vascularization (Giroux et al., 1999) . MKK4 knockout mice die between E10.5 and 12.5. Although MKK4À/À embryos appear anemic, their deaths have been linked not to defects in vasculogenesis or hematopoiesis but to impaired hepatogenesis (Yang et al., 1997; Ganiatsas et al., 1998; Nishina et al., 1999) . MEK5 knockout mice die at E10.5. Although the reasons for their inviability have not been extensively characterized, MEK5À/À mice display cardiovascular defects before death (Wang et al., 2005) . By contrast, MEK2, MKK3 and MKK6 null embryos are viable but the latter two show defects in T-cell signaling (Lu et al., 1999; Tanaka et al., 2002; Belanger et al., 2003) , indicting that these kinases do not function in developmental vascularization or that their loss can be compensated for by the other MKK.
Whereas ERK1-deficient mice are viable and fertile, demonstrating only defects in T-cell maturation (Pages et al., 1999) , ERK2 knockout mice are embryonic-lethal and die at E7.5-E11, as a result of defects in trophoblast development, leading to decreased placental vascularization (Hatano et al., 2003; Saba-El-Leil et al., 2003) . Knockout of p38alpha MAPK causes embryonic lethality starting at E10.5 that is characterized by cardiovascular defects in the embryo that arise secondarily to defects in placental vascularization (Adams et al., 2000; Mudgett et al., 2000) and defective hematopoeisis (Tamura et al., 2000) . By contrast, p38beta MAPK knockouts are viable and apparently healthy. Targetted inactivation of either JNK1 nor JNK2 does not impact embryonic vascularization but instead causes defects in T-cell development (Dong et al., 1998; Yang et al., 1998) . ERK5 knockouts die at E10-E11 not because of an inability to form primary vasculature but because of an inability to remodel that vasculature to form embryonic blood vessels (Regan et al., 2002; Sohn et al., 2002) . Notably, ERK5 deficiency is accompanied by increased expression of VEGF (Sohn et al., 2002) , indicating that ERK5 can regulate expression of angiogenic factors during development. In addition to its role in blood vessel formation during development, ERK5 also plays an important role in maintaining endothelial function and vascular integrity in adults since its conditional inactivation causes increased vascular permeability and hemorrhage in multiple organs (Hayashi et al., 2004) . Abbreviations: ERK, extracellular signal-regulated kinases; JNK, jun kinases; MAPK, mitogen-activated protein kinase; MKK, mitogen-activated protein kinase kinases; MEKK, mitogen-activated protein kinase kinase kinase; MAPKK, mitogen-activated protein kinase kinase.
Further evidence for a role for MKK signaling in vascularization comes from studies of growth factorinduced angiogenesis in chick chorioallantoic membrane. In this system, fibroblast growth factor-induced angiogenesis causes sustained ERK activity in endothelial cells and can be blocked by inhibition of Raf-1 (Hood et al., 2003) or MEK1 and MEK2 activity (Eliceiri et al., 1998) . Interestingly, although fibroblast growth factor also causes sustained activation of p38 MAPK, p38 MAPK inhibition with SB202190 does not inhibit neovascularization but rather enhances it (Matsumoto et al., 2002) , indicating that balanced p38 MAPK activity may be essential for neovascularization of chick chorioallantoic membrane.
Collectively, the preceding studies indicate that the in vivo activities of B-Raf likely acting through MEK1 and ERK2, as well as Mekk3, acting through MEK5, ERK5 and p38alpha MAPK, are essential for vascularization and blood vessel patterning of the placenta (MEK1, ERK2) and embryo proper (Mekk3, ERK5, p38alpha MAPK) during early (E10-11) development. However, despite in vitro evidence supporting a role for MKK signaling in VEGF regulation, the loss of neither MEK2, MKK3, MKK4, MKK6, Erk1, p38beta MAPK, JNK1 nor JNK2 has a significant impact upon developmental vascularization.
MKK signaling in developmental syndromes
If loss of MKK signaling causes defects in embryonic vascularization, what happens when MKK signaling is upregulated during development? Recently, mutations in genes linked to MKK signaling have been associated with a group of human syndromes that includes cardiofacio-cutaneous (CFC) syndrome (mutations in KRas, MEK1, MEK2 and BRAF) (Niihori et al., 2006; Rodriguez-Viciana et al., 2006) , Noonan syndrome (NS) and LEOPARD syndrome (LS), which are caused by gain-of-function mutations and inactivating mutations in the protein tyrosine phosphatase PTP11 (SHP2), leading to constitutive (Araki et al., 2004; Fragale et al., 2004) or impaired MAPK activation (Kontaridis et al., 2005) , respectively, as well as Costello syndrome (CS), an autosomal dominant disease that has been linked to activating mutations in HRAS (Aoki et al., 2005; Estep et al., 2006) . Each causes a similar array of phenotypic consequences including facial dysmorphia, abnormal growth and, notably in this context, cardiovascular defects. Each of these syndromes also carries with it an elevated risk of malignancy. Patients with CS have increased incidence of rhabdomyosarcoma, transitional cell carcinoma and neuroblastoma (Gripp, 2005) ; NS patients of rhabdomyosarcoma, juvenile myelomonocytic leukemia and acute lymphoblastic leukemia (Tartaglia and Gelb, 2005) and LS patients of acute myelogenous leukemia and neuroblastoma (Keren et al., 2004; Merks et al., 2005) . CFC has not been definitively linked with malignancies although they do appear to have increased incidence of hemangiomatoses at birth (Reynolds et al., 1986) . Given the previously described role of MKK signaling in vascular development, it is possible that the increased incidence of malignancies in these patients may be related to altered angioproliferative signaling induced by aberrant MEK 1 or MEK 2 signaling.
Concluding remarks
In vitro data suggest that MKK signalling through ERK, p38MAPK, JNK and ERK5 regulates vital aspects of endothelial function and the release of and response to angioproliferative factors. However, while in vivo data also argue that MKK signaling plays key roles in vascularization during tumorigenesis and development, it is apparent that not all of these pathways are as important as we might have expected based on in vitro work. Why should the in vitro and in vivo importance of these pathways be so different? In vivo, MKK function is likely influenced by intracellular activation of signaling pathways triggered by cell contact with other cells, the extracellular matrix, and other extracellular factors that are transmitted through an integrated vascular network that links adjacent tissues and organs. Thus, the regulation of activity of the MKK signaling pathways may reasonably be expected to be more complex and robust in vivo. Also, it is apparent from in vitro studies that there is ample cross-talk between MKK signaling pathways (see e.g. Xia et al., 1995; MacKeigan et al., 2000) . These results indicate that in vitro cellular responses to stimuli may result from the coordinated activities of multiple MKK pathways. We have not yet begun to consider the complex biology that may arise as a consequence of cross-talk between these pathways within a tissue, organ or whole organism.
